HOME_PAGE_HEADER_CONTENT
Passion for Innovation.
Compassion for Patients.®
Creating New Standards of Care
Creating New Standards of Care
We create essential medicine for longer, better lives.
Learn More About Our PurposeRecentStoryCarousel
Our Stories
Everyone at Daiichi Sankyo has a unique craft - a skill or expertise that they hone with relentless dedication. Our inclusive and diverse community of collaborators apply their individual expertise with compassion to innovate for patients. View More Stories
Informed patients are empowered patients. Which is why helping people with cancer understand their disease, as well as how available treatment options might work for them, is a critical focus of our patient advocacy efforts.
Learn more
Business development is the craft of making connections. Whether with other companies or within our organization, we need to build those bonds that allow us to be successful.
Learn moreTransforming Science into Medicines
Transforming Science into Medicines
By uniting cutting-edge science and technology with a genuine interest in people, we develop high-quality, life-changing solutions for the patients of today and tomorrow with great care and unwavering dedication.
Learn More About Our Science
Dxd Section
Striving to Create Optimized Antibody Drug Conjugate (ADC) Technology
DXd ADC Technology: Our innovations deliver on the benefits of ADC technology.
Featured News
What's New
Read our press releases and learn more about our latest breakthroughs in medicine. View More News
Mon Mar 03 00:00:00 GMT-05:00 2025
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Overall Survival in Patients with HER2 Positive Metastatic Gastric Cancer at Interim Analysis of DESTINY-Gastric04 Phase 3 TrialPositive topline results from the DESTINY-Gastric04 phase 3 trial showed ENHERTU® (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of overall survival (OS) compared to ramucirumab and paclitaxel in patients with second-line HER2 positive (IHC 3+ or IHC 2+/ISH+) unresectable and/or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma
Learn moreThu Jan 30 00:00:00 GMT-05:00 2025
Daiichi Sankyo Appoints Hiroyuki Okuzawa as Chief Executive OfficerDaiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO), effective April 1, 2025
Learn moreNew Home Pipeline
A Pipeline Pushing Us to Become a Global Leader in Oncology
Working with care and dedication, we’re developing new therapies that address the greatest needs in healthcare, making bold strides in cancer and other diseases.
Learn More About Our MedicinesNew Home With Purpose
Work with a Purpose
Be part of something extraordinary. Our people are our most important asset, and we enable them to bring their best selves to work.
Join Our Team